home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2792.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
40 lines
Document 2792
DOCN M94A2792
TI Prevention of severe neutropenia in AIDS patients with intermittent,
low-dose G-CSF (filgrastim).
DT 9412
AU Balbiano R; Degioanni M; Valle M; Crivelli P; Bordino C; Mastinu A;
Biglino A; Department of Infectious Diseases, General Hospital, Asti,
Italy.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):223 (abstract no. PB0323). Unique
Identifier : AIDSLINE ICA10/94369783
AB OBJECTIVE: to evaluate the efficacy of an intermittent, low dosage of
G-CSF in maintaining neutrophil count above 1000/microliters in AIDS
patients at risk of developing severe neutropenia (< 500 microliters).
METHODS: Ten consecutive patients with AIDS and neutrophil counts > 500
< 1000/microliters, treated with zidovudine 500 mg/day, plus either
cotrimoxazole or gancyclovir as secondary prophylaxis, received 5
micrograms/kg/week of G-CSF subcutaneously in two divided doses for 6
months. Neutrophils/microliters were evaluated biweekly, CD4+
cells/microliter monthly, HIV p24 at 0 and 6 months. Presence of
pyogenic/opportunistic infections during follow-up (F.U.) was
investigated weekly. RESULTS are reported in the table. TABULAR DATA,
SEE ABSTRACT VOLUME. CONCLUSIONS: Even at low, intermittent dosage
filgrastim seems to prevent severe neutropenia and its pyogenic
complications in leukopenic patients with AIDS taking potentially
myelotoxic drugs.
DE Acquired Immunodeficiency Syndrome/BLOOD/*COMPLICATIONS/DRUG THERAPY
AIDS-Related Opportunistic Infections/PREVENTION & CONTROL Biological
Response Modifiers/*THERAPEUTIC USE Drug Evaluation Drug Therapy,
Combination Female Ganciclovir/ADVERSE EFFECTS/THERAPEUTIC USE
Granulocyte Colony-Stimulating Factor/*THERAPEUTIC USE Human HIV Core
Protein p24/BLOOD Leukocyte Count Male Neutropenia/CHEMICALLY
INDUCED/*PREVENTION & CONTROL/THERAPY Recombinant Proteins/THERAPEUTIC
USE Treatment Outcome Trimethoprim-Sulfamethoxazole
Combination/THERAPEUTIC USE T4 Lymphocytes Zidovudine/ADVERSE
EFFECTS/THERAPEUTIC USE MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).